Faeth Therapeutics (FTH) vs Silence Therapeutics Plc American Depository Share (SLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Faeth Therapeutics (FTH) has outperformed Silence Therapeutics Plc American Depository Share (SLN) over the past year, gaining 121.4% versus a gain of 91.1%. Over five years, SLN leads with a -55.0% price change compared with -83.7% for FTH. Faeth Therapeutics is the larger company by market cap ($620.8 million vs $565.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FTH | SLN |
|---|---|---|
| Share price | $24.03 | $9.10 |
| Market cap | $620.82M | $565.60M |
| 1-day change | -3.59% | -7.33% |
| YTD return | +133.55% | +61.51% |
| 1-year return | +121.39% | +91.05% |
| 5-year return | -83.67% | -55.00% |
| EPS (TTM) | $-60.86 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $42.14 | $17.58 |
| 52-week low | $7.45 | $4.19 |
| Distance from 52-week high | -42.99% | -48.22% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +135.88% | +262.64% |
| Average volume | 351.88K | 1.12M |
| Shares outstanding | 25.84M | 62.15M |
| Employees | 29 | 88 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FTH has outperformed SLN by 30.3 percentage points over the past year.
About Faeth Therapeutics
FTH stock →Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Silence Therapeutics Plc American Depository Share
SLN stock →Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
FTH vs SLN FAQ
Which is bigger, Faeth Therapeutics or Silence Therapeutics Plc American Depository Share?
Faeth Therapeutics (FTH) is larger, with a market capitalization of $620.82M compared with $565.60M for Silence Therapeutics Plc American Depository Share (SLN).
Which stock has performed better over the past year, FTH or SLN?
FTH returned +121.39% over the past 12 months, compared with +91.05% for SLN (price return, excluding dividends). Past performance does not predict future results.
Are Faeth Therapeutics and Silence Therapeutics Plc American Depository Share in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.